QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
NASDAQ:KNTE

Kinnate Biopharma (KNTE) Price Target & Analyst Ratings

$3.68
-0.37 (-9.14%)
(As of 05/18/2023 ET)
Compare
Today's Range
$3.53
$4.15
50-Day Range
$2.33
$6.84
52-Week Range
$2.32
$15.86
Volume
566,708 shs
Average Volume
296,540 shs
Market Capitalization
$171.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.80

Kinnate Biopharma Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 5 Analyst Ratings

Consensus Analyst Price Target

$19.80
438.04% Upside
High Prediction$30.00
Average Prediction$19.80
Low Prediction$5.00
TypeCurrent
5/18/22 to 5/18/23
1 Month Ago
4/18/22 to 4/18/23
3 Months Ago
2/17/22 to 2/17/23
1 Year Ago
5/18/21 to 5/18/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
5 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$19.80$22.20$26.40$38.75
Predicted Upside438.04% Upside160.81% Upside148.40% Upside168.54% Upside
Get Kinnate Biopharma Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for KNTE and its competitors with MarketBeat's FREE daily newsletter.


KNTE Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

KNTE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Kinnate Biopharma Stock vs. The Competition

TypeKinnate BiopharmaMedical CompaniesS&P 500
Consensus Rating Score
2.80
2.66
2.48
Consensus RatingModerate BuyBuyHold
Predicted Upside450.00% Upside1,401.56% Upside169.89% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/18/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$25.00 ➝ $24.00+492.59%
4/19/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$29.00 ➝ $26.00+678.44%
4/18/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$8.00 ➝ $5.00+21.36%
4/18/2023Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$25.00 ➝ $14.00+165.15%
5/18/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$52.00 ➝ $30.00+201.20%
(Data available from 5/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












KNTE Price Target - Frequently Asked Questions

What is Kinnate Biopharma's consensus rating and price target?

According to the issued ratings of 5 analysts in the last year, the consensus rating for Kinnate Biopharma stock is Moderate Buy based on the current 1 hold rating and 4 buy ratings for KNTE. The average twelve-month price prediction for Kinnate Biopharma is $19.80 with a high price target of $30.00 and a low price target of $5.00. Learn more on KNTE's analyst rating history.

Do Wall Street analysts like Kinnate Biopharma more than its competitors?

Analysts like Kinnate Biopharma more than other Medical companies. The consensus rating for Kinnate Biopharma is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how KNTE compares to other companies.

Does Kinnate Biopharma's stock price have much upside?

According to analysts, Kinnate Biopharma's stock has a predicted upside of 264.57% based on their 12-month price targets.

What analysts cover Kinnate Biopharma?

Kinnate Biopharma has been rated by HC Wainwright, Stifel Nicolaus, The Goldman Sachs Group, and Wedbush in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:KNTE) was last updated on 5/18/2023 by MarketBeat.com Staff

My Account -